Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -1220.49% is in line with its 5-year average of -1127.73%, around the middle of its 5-year range (-1893.87%–-61.84%).
7.96% above its 12-month average of -1326.05%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1690.39%.
OPERATING MARGIN
-1220.49%
OPERATING MARGIN AVG TTM
-1326.05%
OPERATING MARGIN AVG 3Y
-1334.93%
OPERATING MARGIN AVG 5Y
-1127.73%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+7.96%
CURRENT VS 3Y AVG
+8.57%
CURRENT VS 5Y AVG
-8.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Caribou Biosciences, Inc.
Market Cap
$118.02M
Operating Margin
-1220.49%
TTM Avg
-1326.05%
3Y Avg
-1334.93%
5Y Avg
-1127.73%
Market Cap
$118.50M
Operating Margin
-754.08%
TTM Avg
-1999.61%
3Y Avg
-1887.55%
5Y Avg
-2072.97%
Market Cap
$117.43M
Operating Margin
-265.64%
TTM Avg
-359.98%
3Y Avg
-411.27%
5Y Avg
-4203.28%
Market Cap
$118.63M
Operating Margin
-33.18%
TTM Avg
-17.71%
3Y Avg
-9.45%
5Y Avg
-4.00%
Market Cap
$119.09M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$116.59M
Operating Margin
-415175.00%
TTM Avg
-405687.50%
3Y Avg
-206404.23%
5Y Avg
-137602.82%
Market Cap
$114.24M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$113.77M
Operating Margin
-255.05%
TTM Avg
-370.20%
3Y Avg
-218.02%
5Y Avg
-145.34%
Market Cap
$111.17M
Operating Margin
28.39%
TTM Avg
14.20%
3Y Avg
7.10%
5Y Avg
4.73%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $118.02M | -1220.49% | -1326.05% | -1334.93% | -1127.73% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | -754.08% | -1999.61% | -1887.55% | -2072.97% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | -265.64% | -359.98% | -411.27% | -4203.28% |
| BGM Group Ltd. (BGM)vs › | $118.63M | -33.18% | -17.71% | -9.45% | -4.00% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.00% | 0.00% | 0.00% | 0.00% |
| Genelux Corporation (GNLX)vs › | $116.59M | -415175.00% | -405687.50% | -206404.23% | -137602.82% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -255.05% | -370.20% | -218.02% | -145.34% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 28.39% | 14.20% | 7.10% | 4.73% |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
67.3%
Operating Margin
-1220.5%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -1690.39% |
| 2026-03-31 | -1096.37% |
| 2025-12-31 | -721.97% |
| 2025-09-30 | -1337.58% |
| 2025-06-30 | -1783.95% |
| 2025-03-31 | -1823.76% |
| 2024-12-31 | -1871.69% |
| 2024-09-30 | -1889.23% |
| 2024-06-30 | -1255.80% |
| 2024-03-31 | -1893.87% |
| 2023-12-31 | -1052.33% |
| 2023-09-30 | -61.84% |
| 2023-06-30 | -875.31% |
| 2023-03-31 | -888.52% |
| 2022-12-31 | -828.22% |
| 2022-09-30 | -803.42% |
| 2022-06-30 | -678.22% |
| 2022-03-31 | -782.77% |
| 2021-12-31 | -797.38% |
| 2021-09-30 | -468.09% |
| 2021-06-30 | -1081.57% |
| 2021-03-31 | -830.71% |
| 2020-12-31 | -1546.04% |
| 2020-09-30 | -686.89% |
| 2020-06-30 | -26.60% |
| 2020-03-31 | -613.11% |
